A detailed history of Charles Schwab Investment Management Inc transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,913,144 shares of IOVA stock, worth $17.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,913,144
Previous 1,984,945 3.62%
Holding current value
$17.4 Million
Previous $15.9 Million 12.85%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$7.28 - $11.9 $522,711 - $854,431
-71,801 Reduced 3.62%
1,913,144 $18 Million
Q2 2024

Aug 12, 2024

BUY
$7.78 - $14.19 $558,954 - $1.02 Million
71,845 Added 3.76%
1,984,945 $15.9 Million
Q1 2024

May 08, 2024

BUY
$7.59 - $17.47 $1.26 Million - $2.9 Million
166,077 Added 9.51%
1,913,100 $28.4 Million
Q4 2023

Feb 06, 2024

BUY
$3.3 - $8.89 $179,817 - $484,416
54,490 Added 3.22%
1,747,023 $14.2 Million
Q3 2023

Nov 08, 2023

BUY
$4.44 - $8.79 $893,820 - $1.77 Million
201,311 Added 13.5%
1,692,533 $7.7 Million
Q2 2023

Aug 09, 2023

BUY
$5.36 - $9.06 $2.33 Million - $3.94 Million
435,370 Added 41.23%
1,491,222 $10.5 Million
Q1 2023

May 11, 2023

BUY
$5.53 - $8.22 $5,574 - $8,285
1,008 Added 0.1%
1,055,852 $6.45 Million
Q4 2022

Feb 13, 2023

BUY
$5.62 - $10.0 $153,898 - $273,840
27,384 Added 2.67%
1,054,844 $6.74 Million
Q3 2022

Nov 14, 2022

BUY
$9.53 - $13.11 $257,195 - $353,812
26,988 Added 2.7%
1,027,460 $9.84 Million
Q2 2022

Aug 15, 2022

BUY
$6.38 - $18.33 $1.87 Million - $5.37 Million
292,976 Added 41.41%
1,000,472 $11 Million
Q1 2022

May 13, 2022

BUY
$12.38 - $19.1 $272,818 - $420,906
22,037 Added 3.21%
707,496 $11.8 Million
Q4 2021

Feb 11, 2022

BUY
$16.55 - $27.63 $323,767 - $540,525
19,563 Added 2.94%
685,459 $13.1 Million
Q3 2021

Nov 16, 2021

SELL
$20.35 - $26.63 $1.82 Million - $2.38 Million
-89,520 Reduced 11.85%
665,896 $16.4 Million
Q2 2021

Aug 16, 2021

BUY
$16.33 - $33.07 $763,558 - $1.55 Million
46,758 Added 6.6%
755,416 $19.7 Million
Q1 2021

May 17, 2021

BUY
$28.67 - $52.59 $1.7 Million - $3.12 Million
59,401 Added 9.15%
708,658 $22.4 Million
Q4 2020

Feb 16, 2021

BUY
$28.04 - $50.26 $291,251 - $522,050
10,387 Added 1.63%
649,257 $30.1 Million
Q3 2020

Nov 13, 2020

BUY
$27.75 - $36.3 $371,378 - $485,802
13,383 Added 2.14%
638,870 $21 Million
Q2 2020

Aug 14, 2020

SELL
$27.21 - $41.0 $3.18 Million - $4.79 Million
-116,823 Reduced 15.74%
625,487 $17.2 Million
Q1 2020

May 15, 2020

BUY
$19.54 - $38.85 $250,366 - $497,785
12,813 Added 1.76%
742,310 $22.2 Million
Q4 2019

Feb 07, 2020

BUY
$17.95 - $29.41 $512,723 - $840,067
28,564 Added 4.08%
729,497 $20.2 Million
Q3 2019

Nov 08, 2019

SELL
$17.99 - $26.0 $23,764 - $34,346
-1,321 Reduced 0.19%
700,933 $12.8 Million
Q2 2019

Aug 09, 2019

BUY
$9.78 - $24.52 $337,214 - $845,449
34,480 Added 5.16%
702,254 $17.2 Million
Q1 2019

May 14, 2019

BUY
$8.41 - $11.26 $245,521 - $328,724
29,194 Added 4.57%
667,774 $6.35 Million
Q4 2018

Feb 14, 2019

BUY
$7.51 - $11.93 $1.33 Million - $2.11 Million
176,564 Added 38.22%
638,580 $5.65 Million
Q3 2018

Nov 13, 2018

BUY
$11.25 - $17.7 $622,395 - $979,234
55,324 Added 13.6%
462,016 $5.2 Million
Q2 2018

Aug 08, 2018

BUY
$12.45 - $16.95 $606,277 - $825,414
48,697 Added 13.6%
406,692 $5.21 Million
Q1 2018

May 07, 2018

BUY
$8.1 - $19.5 $452,142 - $1.09 Million
55,820 Added 18.47%
357,995 $6.05 Million
Q4 2017

Jan 17, 2018

BUY
$6.65 - $9.25 $533,064 - $741,480
80,160 Added 36.11%
302,175 $2.42 Million
Q3 2017

Nov 13, 2017

BUY
$4.45 - $8.55 $987,966 - $1.9 Million
222,015
222,015 $1.72 Million

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.43B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.